Reimagining Drug Discovery with AI
We design and develop novel oncology therapeutics using an AI-native approach that accelerates discovery and improves outcomes.
ABOUT US
Diskover Diagnostics is an AI-native biotechnology company focused on discovering and developing novel cancer therapeutics.
We combine advances in machine learning, computational biology, and experimental science to rethink how drugs are discovered — moving faster, making smarter decisions, and focusing on what matters most: delivering better therapies to patients.
OUR APPROACH
We take a simulation-first approach to drug discovery.
Instead of relying solely on trial-and-error experimentation, we use advanced computational models to guide decisions early — helping identify promising molecules, reduce risk, and focus downstream validation efforts.
Our work integrates:
-
AI-driven molecule design
-
Predictive modeling of drug behavior
-
Iterative validation across lab, preclinical and clinical settings
FOCUS
We are currently focused on oncology, where the need for faster, more effective therapies remains critical.
Our approach is designed to:
-
Explore novel chemical space
-
Identify high-potential candidates early
-
Advance them efficiently toward development
PLATFORM
Our discovery efforts are powered by our proprietary AI engine, therapeutics.digital.
This internal platform enables us to rapidly generate, evaluate, and optimize drug candidates — forming the backbone of our discovery pipeline.